Carbohydrate Restriction and Prostate Cancer Growth (CAPS2)

This study is currently recruiting participants.
Verified April 2014 by Duke University
Information provided by (Responsible Party):
Duke University Identifier:
First received: December 14, 2012
Last updated: April 2, 2014
Last verified: April 2014

No treatments have been shown to slow prostate cancer progression after radical prostatectomy. We hypothesize that a carbohydrate restricted diet will slow prostate cancer growth. A total of 60 men with a rising prostate-specific antigen (PSA) after failed primary treatment will be recruited and randomized to either a low-carbohydrate diet (<20 grams carbohydrates/day) or a no-diet control (standard of care) for 6 months. The primary outcome is PSA doubling time.

Condition Intervention
Prostate Cancer
Behavioral: Low carbohydrate diet

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men With A Rising PSA After Failed Primary Therapy for Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Duke University:

Primary Outcome Measures:
  • PSA doubling time (change in PSA over time) [ Time Frame: Baseline, 3 and 6 months ] [ Designated as safety issue: No ]
    PSA doubling time will be estimated from PSA measured at baseline, 3 and 6 months post randomization.

Estimated Enrollment: 60
Study Start Date: January 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Low carbohydrate, lifestyle counseling
The Low carbohydrate arm will receive counseling to follow a carbohydrate restriction diet (<20 grams per day) for 6 months.
Behavioral: Low carbohydrate diet
The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
No Intervention: Control
The control arm will receive no dietary intervention.


Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Received prior radical prostatectomy or definitive local radiation for prostate cancer (either external beam radiation, brachytherapy, or combination)
  • PSA within the past 3 months is between 3 and 10 ng/ml
  • PSA doubling time (PSADT) >3 months and <24 months

    1. Calculated based at least 2 values in the prior 2 years with the first and last PSA separated by at least 3 months
    2. Use all values in the last 2 years to calculate PSADT
    3. PSADT calculated while NOT on hormonal therapy
    4. If prior hormonal therapy use, then documented normal testosterone is required before starting to calculate PSADT
  • BMI >25 kg/m2
  • Willing to be randomized to a no-diet control or a low-carbohydrate diet
  • Reads, writes, and understands English

Exclusion Criteria:

  • Anticipate needing secondary prostate cancer therapy within the next 6 months (i.e. radiation, or hormonal therapy)
  • Current use of weight loss medications including herbal weight loss supplements or enrolled in a diet/weight loss program
  • Currently on therapy aimed at altering testosterone levels (includes gonadotropin-releasing hormone (GnRH) agonist/antagonist, prior bilateral orchiectomy, oral anti-androgens, or 5-alpha reductase inhibitors)
  • Known distant metastatic disease
  • Already consuming a carbohydrate-restricted or vegetarian diet
  • Unable or unwilling to adhere to a carbohydrate-restricted dietary intervention
  • Weight loss >5% of body weight in the last 6 months
  • Medical comorbidities that in the opinion of the investigator limits the patient's ability to complete this study
  Contacts and Locations
Please refer to this study by its identifier: NCT01763944

United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27702
Contact: Jordan Smith, RD    919-660-6719   
Principal Investigator: Pao-Hwa Lin, PhD         
Sponsors and Collaborators
Duke University
Principal Investigator: Pao-Hwa Lin Duke University
  More Information

No publications provided

Responsible Party: Duke University Identifier: NCT01763944     History of Changes
Other Study ID Numbers: Pro00041857, 1K24CA160653-01A1
Study First Received: December 14, 2012
Last Updated: April 2, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Duke University:
prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on April 15, 2014